Skip to main
NVCR
NVCR logo

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure Ltd is positioned for potential revenue acceleration due to a recent study that may allow Glioblastoma (GBM) patients to start treatment 2-3 months earlier, which could increase revenue per patient by approximately 20-30%. The company anticipates growth in active patients, particularly in the United States and Germany, which is expected to serve as a leading indicator for revenue growth through 2026. Additionally, NovoCure is expected to begin seeing incremental revenue from new markets within the next 12-18 months, further enhancing its revenue growth drivers.

Bears say

NovoCure Ltd is projected to experience a significant decline in EBITDA as revenue growth gradually increases over the forthcoming quarters, which is anticipated to ultimately reach breakeven levels by 2027. The reliance on a slow ramp-up in revenues raises concerns regarding the company’s ability to manage operating costs effectively in the interim. Additionally, this extended timeline to reach EBITDA breakeven may indicate ongoing financial strain and uncertainty regarding the commercialization success of its Tumor Treating Fields devices and pipeline products.

Novocure (NVCR) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 7 analysts, Novocure (NVCR) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.